[
1. Gołos A, Jesionek-Kupnicka D, Gil L, Braun M, Komarnicki M, Robak T, et al. The Expression of the SLIT-ROBO Family in Adult Patients with Acute Myeloid Leukemia. Arch Immunol Ther Exp (Warsz). 2019;67(2):109-23. DOI: 10.1007/s00005-019-00535-8642049230820596
]Open DOISearch in Google Scholar
[
2. Ueda N, Fujita K, Okuno Y, Nakatani K, Mio T. Therapy-related acute myeloid leukemia after chemotherapy in extensive disease-small cell lung cancer. Clin Case Rep. 2018;7(1):100-3. DOI: 10.1002/ccr3.1931633274130656018
]Open DOISearch in Google Scholar
[
3. He X, Li W, Liang X, Zhu X, Zhang L, Huang Y, et al. IGF2BP2 Overexpression Indicates Poor Survival in Patients with Acute Myelocytic Leukemia. Cell Physiol Biochem. 2018;51(4):1945-56. DOI: 10.1159/00049571930513526
]Open DOISearch in Google Scholar
[
4. Prochazka KT, Pregartner G, Rücker FG, Heitzer E, Pabst G, Wölfler A, et al. Clinical implications of subclonal TP53 mutations in acute myeloid leukemia. Haematologica. 2019;104(3):516-23. DOI: 10.3324/haematol.2018.205013639534130309854
]Open DOISearch in Google Scholar
[
5. Stomper J, Ihorst G, Suciu S, Sander PN, Becker H, Wijermans PW, et al. Fetal hemoglobin induction during decitabine treatment of elderly patients with high-risk myelodysplastic syndrome or acute myeloid leukemia: a potential dynamic biomarker of outcome. Haematologica. 2019;104(1):59-69. DOI: 10.3324/haematol.2017.187278631201430171030
]Open DOISearch in Google Scholar
[
6. Wang F, Tian X, Zhou J, Wang G, Yu W, Li Z, et al. A three lncRNA signature for prognosis prediction of acute myeloid leukemia in patients. Mol Med Rep. 2018;18(2):1473-84. DOI: 10.3892/mmr.2018.9139607222029901168
]Open DOISearch in Google Scholar
[
7. Leukemia & Lymphoma Group, Chinese Society of Hematology, Chinese Medical Association. Chinese guidelines for diagnosis and treatment of adult acute myeloid leukemia (not APL) (2017 Edition). Zhonghua Xue Ye Xue Za Zhi. 2017;38(3):177-82.
]Search in Google Scholar
[
8. Min JW, Koh Y, Kim DY, Kim HL, Han JA, Jung YJ, et al. Identification of novel functional variants of sin3a and srsf1 among somatic variants in acute myeloid leukemia patients. Mol Cells. 2018;41(5):465-75.
]Search in Google Scholar
[
9. Ma L, Kuai WX, Sun XZ, Lu XC, Yuan YF. Long noncoding RNA LINC00265 predicts the prognosis of acute myeloid leukemia patients and functions as a promoter by activating PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 2018;22(22):7867-76.
]Search in Google Scholar
[
10. Bani-Ahmad MA, Al-Sweedan SA, Al-Asseiri MA, Alkhatib AJ. A Proposed kinetic model for the diagnostic and prognostic value of wt1 and p53 in acute myeloid leukemia. Clin Lab. 2018;64(3):357-63. DOI: 10.7754/Clin.Lab.2017.17091529739109
]Open DOISearch in Google Scholar
[
11. Ollila TA, Olszewski AJ, Butera JN, Quesenberry MI, Quesenberry PJ, Reagan JL. Marrow hypocellularity, but not residual blast count or receipt of reinduction chemotherapy, is prognostic on day-14 assessment in acute myeloid leukemia patients with morphologic residual disease. Clin Lymphoma Myeloma Leuk. 2018;18(3):204-9. DOI: 10.1016/j.clml.2018.01.00729433979
]Open DOISearch in Google Scholar
[
12. Lacombe F, Campos L, Allou K, Arnoulet C, Delabarthe A, Dumezy F, et al. Prognostic value of multicenter flow cytometry harmonized assessment of minimal residual disease in acute myeloblastic leukemia. Hematol Oncol. 2018;36(2):422-8. DOI: 10.1002/hon.248829218734
]Open DOISearch in Google Scholar
[
13. Khalil MMI, Lipton JH, Atenafu EG, Gupta V, Kim DD, Kuruvilla J, et al. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia. Eur J Haematol. 2018;100(2):198-205. DOI: 10.1111/ejh.1300029168234
]Open DOISearch in Google Scholar
[
14. Zhou JD, Yao DM, Li XX, Zhang TJ, Zhang W, Ma JC, et al. KRAS overexpression independent of RAS mutations confers an adverse prognosis in cytogenetically normal acute myeloid leukemia. Oncotarget. 2017;8(39):66087-97. DOI: 10.18632/oncotarget.19798563039429029494
]Open DOISearch in Google Scholar
[
15. Elhamamsy AR, El Sharkawy MS, Zanaty AF, Mahrous MA, Mohamed AE, Abushaaban EA. Circulating miR-92a, miR-143 and miR-342 in Plasma are Novel Potential Biomarkers for Acute Myeloid Leukemia. Int J Mol Cell Med. 2017;6(2):77-86.
]Search in Google Scholar
[
16. Vidal V, Robert G, Goursaud L, Durand L, Ginet C, Karsenti JM, et al. BCL2L10 positive cells in bone marrow are an independent prognostic factor of azacitidine outcome in myelodysplastic syndrome and acute myeloid leukemia. Oncotarget. 2017;8(29):47103-9. DOI: 10.18632/oncotarget.17482556454728514758
]Open DOISearch in Google Scholar
[
17. Isidori A, Loscocco F, Curti A, Amadori S, Visani G. Genomic profiling and predicting treatment response in acute myeloid leukemia. Pharmacogenomics. 20: 467-470, 2019. DOI: 10.2217/pgs-2018-020231124415
]Open DOISearch in Google Scholar
[
18. McMahon CM, Canaani J, Rea B, et al. Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia. Blood Adv 2019;20(7):467-70. DOI: 10.1182/bloodadvances.2018029496653887031122910
]Open DOISearch in Google Scholar
[
19. Xiao PF, Tao YF, Hu SY, Cao L, Lu J, Wang J, et al. mRNA expression profiling of histone modifying enzymes in pediatric acute monoblastic leukemia. Pharmazie. 2017;72(3):177-86.
]Search in Google Scholar
[
20. Chae HD, Cox N, Dahl GV, Lacayo NJ, Davis KL, Capolicchio S, et al. Niclosamide suppresses acute myeloid leukemia cell proliferation through inhibition of CREB-dependent signaling pathways. Oncotarget. 2017;9(4):4301-17. DOI: 10.18632/oncotarget.23794579697529435104
]Open DOISearch in Google Scholar
[
21. Safaei A, Monabati A, Mokhtari M, Safavi M, Solhjoo F. Evaluation of the CD123 Expression and FLT3 Gene Mutations in Patients with Acute Myeloid Leukemia. Iran J Pathol. 2018;13(4):438-46.
]Search in Google Scholar
[
22. Elkeeb D, Hopkins Z, Miles RR, Halwani A, Wada D. Ominous cutaneous presentation of acute myeloid leukemia without peripheral blood involvement upon initial presentation and relapse: case report and literature review. Eur J Dermatol. 2018;28(6):809-17.
]Search in Google Scholar
[
23. Alcalay M, Tiacci E, Bergomas R, Bigerna B, Venturini E, Minardi SP, et al. Acute myeloid leukemia bearing cytoplasmic nucleophosmin (NPMc+ AML) shows a distinct gene expression profile characterized by up-regulation of genes involved in stem-cell maintenance. Blood. 2005;106(3):899-902. DOI: 10.1182/blood-2005-02-056015831697
]Open DOISearch in Google Scholar
[
24. Au WY, Fung A, Chim CS, Lie AK, Liang R, Ma ES, et al. FLT-3 aberrations in acute promyelocytic leukaemia: clinicopathological associations and prognostic impact. Br J Haematol. 2004;125(4):463-9. DOI: 10.1111/j.1365-2141.2004.04935.x15142116
]Open DOISearch in Google Scholar
